Amneal Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ (Deficiency) Equity
| Class A Common Stock · AdditionalPaid-in Capital · Stockholders’Accumulated Deficit · AccumulatedOtherComprehensive Loss · Non-Controlling Interests · Total (Deficiency) Equity · Redeemable Non-Controlling Interests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||
| Balance at March 31, 2026 | 318,998 | $3,190 | $536,299 | $(472,749) | $(112,151) | $(558) | $(45,969) | $85,912 |
| Net income (loss) | — | — | — | 57,662 | — | (12) | 57,650 | 11,964 |
| Foreign currency translation adjustments | — | — | — | — | (1,074) | — | (1,074) | — |
| Stock-based compensation | — | — | 10,392 | — | — | — | 10,392 | — |
| Exercise of stock options | 15 | — | 42 | — | — | — | 42 | — |
| Shares issued upon vesting of stock-based compensation awards | 317 | 3 | (179) | — | — | — | (176) | — |
| Unrealized gain on cash flow hedge, net of tax of $0 | — | — | — | — | 6,062 | — | 6,062 | — |
| Tax and other distributions, net | — | — | — | — | — | — | — | (13,920) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | — | — | — | — | 2,910 | — | 2,910 | — |
| Acquisition of non-controlling interests | — | — | (970) | — | — | 570 | (400) | — |
| Other, net of tax of $0 | — | — | — | — | 3,587 | — | 3,587 | — |
| Balance at June 30, 2026 | 319,330 | $3,193 | $545,584 | $(415,087) | $(100,666) | $— | $33,024 | $83,956 |
| Class A Common Stock · AdditionalPaid-in Capital · Stockholders’Accumulated Deficit · AccumulatedOtherComprehensive Loss · Non-Controlling Interests · Total (Deficiency) Equity · Redeemable Non-Controlling Interests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||
| Balance at December 31, 2025 | 314,565 | $3,146 | $571,794 | $(535,005) | $(110,729) | $(535) | $(71,329) | $77,292 |
| Net income (loss) | — | — | — | 119,918 | — | (35) | 119,883 | 27,731 |
| Foreign currency translation adjustments | — | — | — | — | (9,904) | — | (9,904) | — |
| Stock-based compensation | — | — | 19,208 | — | — | — | 19,208 | — |
| Exercise of stock options | 29 | — | 80 | — | — | — | 80 | — |
| Shares issued upon vesting of stock-based compensation awards | 4,736 | 47 | (44,528) | — | — | — | (44,481) | — |
| Unrealized gain on cash flow hedge, net of tax of $0 | — | — | — | — | 10,456 | — | 10,456 | — |
| Tax and other distributions, net | — | — | — | — | — | — | — | (21,067) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | — | — | — | — | 5,788 | — | 5,788 | — |
| Acquisition of non-controlling interests | — | — | (970) | — | — | 570 | (400) | — |
| Other, net of tax of $0 | — | — | — | — | 3,723 | — | 3,723 | — |
| Balance at June 30, 2026 | 319,330 | $3,193 | $545,584 | $(415,087) | $(100,666) | $— | $33,024 | $83,956 |
Consolidated Statements of Changes in Stockholders’ (Deficiency) Equity
| Class A CommonStock · AdditionalPaid-in Capital · Stockholders’Accumulated Deficit · AccumulatedOtherComprehensive Loss · Non-Controlling Interests · Total Deficiency · Redeemable Non-Controlling Interests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||
| Balance at March 31, 2025 | 313,385 | $3,134 | $545,806 | $(594,867) | $(85,740) | $(333) | $(132,000) | $72,611 |
| Net income (loss) | — | — | — | 22,417 | — | (82) | 22,335 | 13,275 |
| Foreign currency translation adjustments | — | — | — | — | (4,928) | — | (4,928) | — |
| Stock-based compensation | — | — | 8,274 | — | — | — | 8,274 | — |
| Exercise of stock options | 249 | 2 | 683 | — | — | — | 685 | — |
| Shares issued upon vesting of stock-based compensation awards | 409 | 4 | (140) | — | — | — | (136) | — |
| Unrealized loss on cash flow hedge, net of tax of $0 | — | — | — | — | (7,331) | — | (7,331) | — |
| Tax and other distributions, net | — | — | — | — | — | — | — | (20,084) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | — | — | — | — | 568 | — | 568 | — |
| Balance at June 30, 2025 | 314,043 | $3,140 | $554,623 | $(572,450) | $(97,431) | $(415) | $(112,533) | $65,802 |
| Class A CommonStock · AdditionalPaid-in Capital · Stockholders’Accumulated Deficit · AccumulatedOtherComprehensive Loss · Non-Controlling Interests · Total Deficiency · Redeemable Non-Controlling Interests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||
| Balance at December 31, 2024 | 309,881 | $3,099 | $560,206 | $(607,062) | $(65,510) | $(245) | $(109,512) | $64,974 |
| Net income (loss) | — | — | — | 34,612 | — | (170) | 34,442 | 25,786 |
| Foreign currency translation adjustments | — | — | — | — | (6,560) | — | (6,560) | — |
| Stock-based compensation | — | — | 15,532 | — | — | — | 15,532 | — |
| Exercise of stock options | 274 | 2 | 752 | — | — | — | 754 | — |
| Shares issued upon vesting of stock-based compensation awards | 3,888 | 39 | (21,867) | — | — | — | (21,828) | — |
| Unrealized loss on cash flow hedge, net of tax of $0 | — | — | — | — | (19,485) | — | (19,485) | — |
| Tax and other distributions, net | — | — | — | — | — | — | — | (24,958) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | — | — | — | — | (5,876) | — | (5,876) | — |
| Balance at June 30, 2025 | 314,043 | $3,140 | $554,623 | $(572,450) | $(97,431) | $(415) | $(112,533) | $65,802 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.